Pathogenesis of giant cell arteritis: New insight into the implication of CD161+ T cells

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.75, 2013, Pages

  Samson, M ^a,c   Audia, S ^a,c   Martin, L ^a,b   Janikashvili, N ^b,c   Bonnotte, B ^a,c  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

CD161; Giant cell arteritis; Interleukin 6; Regulatory T cells; T cell; Th1 cells; Th17 cells

Indexed keywords

GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; TOCILIZUMAB;

ANTIGEN EXPRESSION; AORTA; ARTERY INTIMA PROLIFERATION; BLOOD VESSEL WALL; CAROTID ARTERY; CD161+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL INFILTRATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG TARGETING; GIANT CELL; GIANT CELL ARTERITIS; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOLOGY; ISCHEMIA; MACROPHAGE; MACROPHAGE ACTIVATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; SYMPTOM; T LYMPHOCYTE; TH1 CELL; TH17 CELL; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTERIES; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CHEMOTAXIS, LEUKOCYTE; GIANT CELL ARTERITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-6; MACROPHAGES; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY B; TH1 CELLS; TH17 CELLS;

EID: 84878421407     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. JENNETTE JC, FALK RJ, ANDRASSY K et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
2. JENNETTE JC, FALK RJ, BACON PA et al.: 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013; 65: 1-11.
3. SALVARANI C, CANTINI F, HUNDER GG: Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372: 234-45.
4. SALVARANI C, MACCHIONI P, ZIZZI F et al.: Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991; 34: 351-6.
5. CHAUDHRY IA, SHAMSI FA, ELZARIDI E, ARAT YO, BOSLEY TM, RILEY FC: Epidemiology of giant-cell arteritis in an Arab population: a 22-year study. Br J Ophthalmol 2007; 91: 715-8.
6. LEE JL, NAGUWA SM, CHEEMA GS, GERSHWIN ME: The geo-epidemiology of temporal (giant cell) arteritis. Clin Rev Allergy Immunol 2008; 35: 88-95.
7. LUGO JZ, DEITCH JS, YU A et al.: Demographic and laboratory data may predict positive temporal artery biopsy. J Surg Res 2011; 170: 332-5.
8. PEREIRA LS, YOON MK, HWANG TN et al.: Giant cell arteritis in Asians: a comparative study. Br J Ophthalmol 2011; 95: 214-6.
9. SHAH A, JAIN S: Epidemiology of giant cell arteritis in an Arab population: a 22-year study. Ethnic variation in incidence of giant cell arteritis. Br J Ophthalmol 2008; 92: 724-5.
10. SALVARANI C, CROWSON CS, O'FALLON WM, HUNDER GG, GABRIEL SE: Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum 2004; 51: 264-8.
11. FLORES-DOMINGUEZ C, HERNANDEZ-PACHECO G, ZUNIGA J et al.: [Alleles of the major histocompatibility system associated with susceptibility to the development of Takayasu's arteritis]. Gac Med Mex 2002; 138: 177-83.
12. COMBE B, SANY J, LE QUELLEC A, CLOT J, ELIAOU JF: Distribution of HLA-DRB1 alleles of patients with polymyalgia rheumatica and giant cell arteritis in a Mediterranean population. J Rheumatol 1998; 25: 94-8.
13. WEYAND CM, HICOK KC, HUNDER GG, GORONZY JJ: The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest 1992; 90: 2355-61.
14. GONZALEZ-GAY MA: Genetic epidemiology. Giant cell arteritis and polymyalgia rheumatica. Arthritis Res 2001; 3: 154-7.
15. GONZALEZ-GAY MA, HAJEER AH, DABABNEH A et al.: IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. Clin Exp Rheumatol 2002; 20: 179-84.
16. GONZALEZ-GAY MA, HAJEER AH, DABABNEH A et al.: Corticotropin releasing hormone promoter polymorphisms in giant cell arteritis and polymyalgia rheumatica. Clin Exp Rheumatol 2002; 20: 133-8.
17. SERRANO A, CARMONA FD, CASTANEDA S et al.: Evidence of association of the NLRP1 gene with giant cell arteritis. Ann Rheum Dis 2012.
18. DUHAUT P, BOSSHARD S, DUCROIX JP: Is giant cell arteritis an infectious disease? Biological and epidemiological evidence. Presse Med 2004; 33: 1403-8.
19. LY KH, REGENT A, TAMBY MC, MOUTHON L: Pathogenesis of giant cell arteritis: More than just an inflammatory condition? Autoimmun Rev 2010; 9: 635-45.
20. KOENING CL, KATZ BJ, HERNANDEZ-RODRIGUEZ J et al.: Identification of a Burkholderia -Like Strain From Temporal Arteries of Subjects with Giant Cell Arteritis. Arthritis Rheum 2012; 64: S373.
21. AGARD C, BARRIER JH, DUPAS B et al.: Aortic involvement in recent-onset giant cell (temporal) arteritis: a case-control prospective study using helical aortic computed tomodensitometric scan. Arthritis Rheum 2008; 59: 670-6.
22. BORCHERS AT, GERSHWIN ME: Giant cell arteritis: A review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev 2012; 11: A544-54.
23. PROVEN A, GABRIEL SE, ORCES C, O'FALLON WM, HUNDER GG: Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003; 49: 703-8.
24. SALVARANI C, GIANNINI C, MILLER DV, HUNDER G: Giant cell arteritis: Involvement of intracranial arteries. Arthritis Rheum 2006; 55: 985-9.
25. BANCHEREAU J, BRIERE F, CAUX C et al.: Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
26. WEYAND CM, GORONZY JJ: Medium- and large-vessel vasculitis. N Engl J Med 2003; 349: 160-9.
27. KRUPA WM, DEWAN M, JEON MS et al.: Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis. Am J Pathol 2002; 161: 1815-23.
28. MA-KRUPA W, JEON MS, SPOERL S, TEDDER TF, GORONZY JJ, WEYAND CM: Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004; 199: 173-83.
29. MA-KRUPA W, KWAN M, GORONZY JJ, WEYAND CM: Toll-like receptors in giant cell arteritis. Clin Immunol 2005; 115: 38-46.
30. TALARICO R, BALDINI C, DELLA ROSSA A et al.: Large- and small-vessel vasculitis: a critical digest of the 2010-2011 literature. Clin Exp Rheumatol 2012; 30: S130-8.
31. PRYSHCHEP O, MA-KRUPA W, YOUNGE BR, GORONZY JJ, WEYAND CM: Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 2008; 118: 1276-84.
32. BRACK A, GEISLER A, MARTINEZ-TABOADA VM, YOUNGE BR, GORONZY JJ, WEYAND CM: Giant cell vasculitis is a T cell-dependent disease. Mol Med 1997; 3: 530-43.
33. MARTINEZ-TABOADA V, HUNDER NN, HUNDER GG, WEYAND CM, GORONZY JJ: Recognition of tissue residing antigen by T cells in vasculitic lesions of giant cell arteritis. J Mol Med (Berl) 1996; 74: 695-703.
34. MARTINEZ-TABOADA VM, GORONZY JJ, WEYAND CM: Clonally expanded CD8 T cells in patients with polymyalgia rheumatica and giant cell arteritis. Clin Immunol Immunopathol 1996; 79: 263-70.
35. WEYAND CM, SCHONBERGER J, OPPITZ U, HUNDER NN, HICOK KC, GORONZY JJ: Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med 1994; 179: 951-60.
36. PIGGOTT K, BIOUSSE V, NEWMAN NJ, GORONZY JJ, WEYAND CM: Vascular damage in giant cell arteritis. Autoimmunity 2009; 42: 596-604.
37. ANNUNZIATO F, COSMI L, LIOTTA F, MAGGI E, ROMAGNANI S: The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation. Int Immunol 2008; 20: 1361-8.
38. MIOSSEC P, KORN T, KUCHROO VK: Interleukin- 17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-98.
39. SAMSON M, LAKOMY D, AUDIA S, BONNOTTE B: [T(H)17 lymphocytes: Induction, phenotype, functions, and implications in human disease and therapeutic.]. Rev Med Interne 2011; 32: 292-301.
40. DENG J, YOUNGE BR, OLSHEN RA, GORONZY JJ, WEYAND CM: Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010; 121: 906-15.
41. SAMSON M, AUDIA S, FRASZCZAK J et al.: Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum 2012; 64: 3788-98.
42. TERRIER B, GERI G, CHAARA W et al.: Interleukin- 21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum 2012; 64: 2001-11.
43. ESPIGOL-FRIGOLE G, CORBERA-BELLALTA M, PLANAS-RIGOL E et al.: Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Ann Rheum Dis 2012 Sep 19 [Epub].
44. WEYAND CM, YOUNGE BR, GORONZY JJ: IFN-gamma and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol 2011; 23: 43-9.
45. ANNUNZIATO F, ROMAGNANI S: Heterogeneity of human effector CD4+ T cells. Arthritis Res Ther 2009; 11: 257.
46. PECK A, MELLINS ED: Plasticity of T-cell phenotype and function: the T helper type 17 example. Immunology 2010; 129: 147-53.
47. ZHU J, PAUL WE: Heterogeneity and plasticity of T helper cells. Cell Res 2010; 20: 4- 12.
48. FENG T, QIN H, WANG L, BENVENISTE EN, ELSON CO, CONG Y: Th17 cells induce colitis and promote Th1 cell responses through IL-17 induction of innate IL-12 and IL-23 production. J Immunol 2011; 186: 6313-8.
49. COSMI L, DE PALMA R, SANTARLASCI V et al.: Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med 2008; 205: 1903-16.
50. BENDELAC A, SAVAGE PB, TEYTON L: The biology of NKT cells. Annu Rev Immunol 2007; 25: 297-336.
51. GODFREY DI, BERZINS SP: Control points in NKT-cell development. Nat Rev Immunol 2007; 7: 505-18.
52. COSMI L, CIMAZ R, MAGGI L et al.: Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis. Arthritis Rheum 2011; 63: 2504-15.
53. TANG Q, BLUESTONE JA: The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008; 9: 239-44.
54. GE W, MA X, LI X et al.: B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells. Leuk Res 2009; 33: 948-57.
55. NASRALLAH M, VAGLIO A, MOHAN S et al.: Impairment of the inhibitory PD-1-PD-L1 axis in giant cell arteritis (GCA). Arthritis Rheum 2012; 64: S374.
56. WEYAND CM, GORONZY JJ: Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003; 139: 505-15.
57. CID MC, HOFFMAN MP, HERNANDEZ-RODRIGUEZ J et al.: Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giantcell arteritis. Rheumatology (Oxford) 2006; 45: 1356-63.
58. ROLLINS BJ: Chemokines. Blood 1997; 90: 909-28.
59. HERNANDEZ-RODRIGUEZ J, SEGARRA M, VILARDELL C et al.: Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003; 107: 2428-34.
60. HERNANDEZ-RODRIGUEZ J, SEGARRA M, VILARDELL C et al.: Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 2004; 43: 294-301.
61. ROCHE NE, FULBRIGHT JW, WAGNER AD, HUNDER GG, GORONZY JJ, WEYAND CM: Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993; 36: 1286-94.
62. KAISER M, WEYAND CM, BJORNSSON J, GORONZY JJ: Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 1998; 41: 623-33.
63. KAISER M, YOUNGE B, BJORNSSON J, GORONZY JJ, WEYAND CM: Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol 1999; 155: 765-74.
64. GALIS ZS, KHATRI JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-62.
65. GONZALEZ-GAY MA, GARCIA-PORRUA C, LLORCA J et al.: Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000; 79: 283-92.
66. BANKS PM, COHEN MD, GINSBURG WW, HUNDER GG: Immunohistologic and cytochemical studies of temporal arteritis. Arthritis Rheum 1983; 26: 1201-7.
67. LAVIGNAC C, JAUBERTEAU-MARCHAN MO, LIOZON E, VIDAL E, CATANZANO G, LIOZON F: [Immunohistochemical study of lesions in Horton's temporal arteritis before and during corticotherapy]. Rev Med Interne 1996; 17: 814-20.
68. CHATELAIN D, DUHAUT P, SCHMIDT J et al.: Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss. Ann Rheum Dis 2009; 68: 84-8.
69. CID MC, CERVERA R, FONT J et al.: Late thrombotic events in patients with temporal arteritis and anticardiolipin antibodies. Clin Exp Rheumatol 1990; 8: 359-63.
70. DUHAUT P, BERRUYER M, PINEDE L et al.: Anticardiolipin antibodies and giant cell arteritis: a prospective, multicenter case-control study. Groupe de Recherche sur l'Arterite a Cellules Geantes. Arthritis Rheum 1998; 41: 701-9.
71. LIOZON E, ROBLOT P, PAIRE D et al.: Anticardiolipin antibody levels predict flares and relapses in patients with giant-cell (temporal) arteritis. A longitudinal study of 58 biopsyproven cases. Rheumatology (Oxford) 2000; 39: 1089-94.
72. LIOZON E, ROUSSEL V, ROBLOT P et al.: Absence of anti-beta2 glycoprotein I antibodies in giant cell arteritis: a study of 45 biopsy-proven cases. Br J Rheumatol 1998; 37: 1129-31.
73. MANNA R, LATTERI M, CRISTIANO G, TODARO L, SCUDERI F, GASBARRINI G: Anticardiolipin antibodies in giant cell arteritis and polymyalgia rheumatica: a study of 40 cases. Br J Rheumatol 1998; 37: 208-10.
74. NAVARRO M, CERVERA R, FONT J et al.: Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance. Lupus 1997; 6: 521-6.
75. SERVETTAZ A, GUILPAIN P, TAMAS N, KAVERI SV, CAMOIN L, MOUTHON L: Natural anti-endothelial cell antibodies. Autoimmun Rev 2008; 7: 426-30.
76. DOMICIANO DS, CARVALHO JF, SHOENFELD Y: Pathogenic role of anti-endothelial cell antibodies in autoimmune rheumatic diseases. Lupus 2009; 18: 1233-8.
77. REGENT A, DIB H, LY KH et al.: Identification of target antigens of anti-endothelial cell and anti-vascular smooth muscle cell antibodies in patients with giant cell arteritis: a proteomic approach. Arthritis Res Ther 2011; 13: R107.
78. BAERLECKEN NT, LINNEMANN A, GROSS WL et al.: Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. Ann Rheum Dis 2012; 71: 943- 7.
79. MOHAN SV, LIAO YJ, KIM JW, GORONZY JJ, WEYAND CM: Giant cell arteritis: immune and vascular aging as disease risk factors. Arthritis Res Ther 2011; 13: 231.
80. CZESNIKIEWICZ-GUZIK M, LEE WW, CUI D et al.: T cell subset-specific susceptibility to aging. Clin Immunol 2008; 127: 107-18.
81. GORONZY JJ, FULBRIGHT JW, CROWSON CS, POLAND GA, O'FALLON WM, WEYAND CM: Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 2001; 75: 12182-7.
82. VALLEJO AN, WEYAND CM, GORONZY JJ: T-cell senescence: a culprit of immune abnormalities in chronic inflammation and persistent infection. Trends Mol Med 2004; 10: 119-24.
83. WEYAND CM, FUJII H, SHAO L, GORONZY JJ: Rejuvenating the immune system in rheumatoid arthritis. Nat Rev Rheumatol 2009; 5: 583-8.
84. GROLLEAU-JULIUS A, HARNING EK, ABERNATHY LM, YUNG RL: Impaired dendritic cell function in aging leads to defective antitumor immunity. Cancer Res 2008; 68: 6341-9.
85. PANDA A, QIAN F, MOHANTY S et al.: Ageassociated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol 2010; 184: 2518-27.
86. CAMPISI J, D'ADDA DI FAGAGNA F: Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8: 729- 40.
87. LEE HY, OH BH: Aging and arterial stiffness. Circ J 2010; 74: 2257-62.
88. LI M, FUKAGAWA NK: Age-related changes in redox signaling and VSMC function. Antioxid Redox Signal 2010; 12: 641-55.
89. SAWABE M: Vascular aging: from molecular mechanism to clinical significance. Geriatr Gerontol Int 2010; 10 (Suppl. 1): S213-20.
90. WANG M, MONTICONE RE, LAKATTA EG: Arterial aging: a journey into subclinical arterial disease. Curr Opin Nephrol Hypertens 2010; 19: 201-7.
91. BETTELLI E, CARRIER Y, GAO W et al.: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-8.
92. KOENEN HJ, SMEETS RL, VINK PM, VAN RIJSSEN E, BOOTS AM, JOOSTEN I: Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008; 112: 2340-52.
93. SAMSON M, AUDIA S, JANIKASHVILI N et al.: Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: 2499-503.
94. CATANOSO MG ML, PIPITONE N, VERSARI A et al.: Tocilizumab: A novel therapy for patients with large-vessel vasculitis. Arthritis Rheum 2011; 63: S588.
95. SALVARANI C, MAGNANI L, CATANOSO M et al.: Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012; 51: 151-6.
96. SEITZ M, REICHENBACH S, BONEL HM, ADLER S, WERMELINGER F, VILLIGER PM: Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011; 141: w13156.
97. UNIZONY S A-UL, MILOSLAVSKY E, ARVIKAR SL, KHOSROSHAHI A, STONE JH: Tocilizumab for the treatment of large vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica: a case series. Arthritis Rheum 2011; 63: S589.